Serum erythropoietin levels in ovarian cancer patients receiving chemotherapy

European Journal of Obstetrics and Gynecology and Reproductive Biology

Volumn 98, Issue 2, 2001, Pages 224-230

  Pedain, C ^a   Herrero, J ^a   Kunzel W ^a  

^a JUSTUS LIEBIG UNIVERSITY   (Germany)

Author keywords

Anaemia; Chemotherapy; Erythropoietin; Ovarian cancer

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; ERYTHROPOIETIN; HEMOGLOBIN;

AGED; ANEMIA; ARTICLE; BLOOD; CHEMICALLY INDUCED DISORDER; DRUG EFFECT; FEMALE; HUMAN; MIDDLE AGED; OVARY TUMOR; PROSPECTIVE STUDY;

AGED; ANEMIA; ANTINEOPLASTIC AGENTS; CISPLATIN; ERYTHROPOIETIN; FEMALE; HEMOGLOBINS; HUMANS; MIDDLE AGED; OVARIAN NEOPLASMS; PROSPECTIVE STUDIES;

EID: 0035489999     PISSN: 03012115     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0301-2115(01)00336-0     Document Type: Article

References (52)

1. Matsumoto T, Endoh K, Kamisango K, et al. Effect of recombinant human erythropoietin on anti-cancer drug-induced anaemia. Br J Haematol 1990;75:463-8.
2. Von Hoff DD, Schilsky R, Reichert CM, et al. Toxic effects of cis-dichlorodiammine-platinum(II) in man. Cancer Treat Rep 1979;63: 1527-31.
3. Rothmann SA, Paul P, Weick JK, et al. Erythropoietin (Epo) production and hematopoietic progenitor cell inhibition after cis-diamminedichloroplatinum (cDDP). Experiment Hematol 1985;13:117.
4. Alexopoulos CG, Chalevelakis G, Katsoulis C, et al. Adverse effect of cis-diamminedichloroplatinum(II) (CDDP) on porphyrin metabolism in man. Cancer Chemother Pharmacol 1986;17:165-70.
5. Smith DH, Goldwasser E, Vokes EE. Serum immunoerythropoietin levels in patients with cancer receiving cis-platin-based chemotherapy. Cancer 1991;68:1101-5.
6. Gradishar WJ, Vokes EE, Ni K, et al. Chemotherapy-related hemolytic-uremic syndrome after the treatment of head and neck cancer. A case report. Cancer 66:1914-8.
7. Jenkins VK, Perry RR, Goodrich WE. Effects of cis-diamminedichloroplatinum(II) on hematopoietic stem cells in mice. Exp Hematol 1981;9:281-7.
8. Wood PA, Hrushesky WJ. Cis-platin-associated anemia: an erythropoietin deficiency syndrome. J Clin Invest 1995;95:1650-9.
9. Rossof AH, Slayton RE, Perlia CP. Preliminary clinical experience with cis-diamminedichloroplatinum(II) (NSC 119875, CACP). Cancer 1972;30:1451-6.
10. Hayes DM, Cvitkovic E, Golbey RB, et al. High dose cis-platinumdiammine dichloride: amelioration of renal toxicity by mannitol diuresis. Cancer 1977;39:1372-81.
11. Gandara DR, Wold H, Perez EA, et al. Cis-platin dose intensity in non-small cell lung cancer: phase II results of a day 1 and day 8 high-dose regimen. J Natl Cancer Inst 1989;81:790-4.
12. Nowrousian MR, Schmidt CG. Effects of cis-platin on different haemopoietic progenitor cells in mice. Br J Cancer 1982;46:397-402.
13. Kuzur ME, Greco FA. Cis-platin-induced anemia. N Engl J Med 1980;303:110-1.
14. Gale RP. Antineoplastic chemotherapy myelosuppression: mechanisms and new approaches. Exp Hematol 1985;13:3-7.
15. Dentino M, Luft FC, Yum MN, et al. Long-term effect of cis-diamminedichloride platinum (CDDP) on renal function and structure in man. Cancer 1978;41:1274-81.
16. Fjeldborg P, Sorensen J, Helkjaer PE. The long-term effect of cis-platin on renal function. Cancer 1986;58:2214-7.
17. Gonzales-Vitale JC, Hayes DM, Cvitkovic E, et al. The renal pathology in clinical trials of cis-platinum(II) diamminedichloride. Cancer 1977;39:1362-71.
18. Zanjani ED, Poster J, Burlington H, et al. Liver as the primary site of erythropoietin formation in the fetus. J Lab Clin Med 1977;89: 640-4.
19. Koury ST, Bondurant MC, Koury MJ. Localization of erythropoietin synthesizing cells in murine kidneys by in situ hybridization. Blood 1988;71:524-7.
20. Lacombe C, Da Silva JL, Bruneval P, et al. Peritubular cells are the site of erythropoietin synthesis in the murine hypoxic kidney. J Clin Invest 1988;81:620-3.
21. Erslev AJ. Erythropoietin. N Engl J Med 1991;324:1339-44.
22. Erslev AJ, Wilson J, Caro J. Erythropoietin titers in anemic, non-uremic patients. J Lab Clin Med 1987;109:429-33.
23. Ireland RM, Atkinson K, Concannon A, et al. Serum erythropoietin changes in autologous and allogeneic bone marrow transplant patients. Br J Haematol 1990;76:128-34.
24. Hellebostad M, Marstrander J, Slordahl SH, et al. Serum immunoreactive erythropoietin in children with acute leukaemia at various stages of disease -and the effects of treatment. Eur J Haematol 1990;44:159-64.
25. Saijo Y, Nakai Y, Saito J, et al. Changes in serum erythropoietin levels during chemotherapy for lung cancer. Chemotherapy 1992;38:281-5.
26. Birgegard G, Wide L, Simonsson B. Marked erythropoietin increase before fall in Hb after treatment with cytostatic drugs suggests mechanism other than anaemia for stimulation. Br J Haematol 1989;72:462-6.
27. Piroso E, Erslev AJ, Caro J. Inappropriate increase in erythropoietin titers during chemotherapy. Am J Hematol 1989;32:254-8.
28. Schapira L, Antin JH, Ransil BJ, et al. Serum erythropoietin levels in patients receiving intensive chemotherapy and radiotherapy. Blood 1990;76: 2354-9.
29. Lechner W, Artner-Dworzak E, Solder E, et al. Influence on erythropoietin levels of treatment with cis-platinum-endoxan. Arch Gynecol Obstet 1992;252:49-53.
30. Cerruti A, Castello G, Balleari E, et al. Serum erythropoietin increase in patients receiving adjuvant therapy with 5-fluorouracil and leucovorin. Exp Hematol 1994;22:1261-3.
31. Hasegawa I, Tanaka K. Serum erythropoietin levels in gynecologic cancer patients during cis-platin combination chemotherapy. Gynecol Oncol 1992;46:65-8.
32. Miller CB, Jones RJ, Piantadosi S, et al. Decreased erythropoietin response in patients with the anemia of cancer. N Engl J Med 1990;322:1689-92.
33. Lee GR. The anemia of chronic disease. Semin Hematol 1983; 20:61-80.
34. Letendre ED. Iron metabolism during infection and neoplasia. Cancer Metastasis Rev 1987;6:41-53.
35. ISIS Research Institute Ltd. Treatment of Cancer in Europe Phase IV, April 1995.
36. Abels RJ, Larholt KM, Krantz KD. Recombinant Human Erythropoietin (r-HuEPO) for the treatment of the anemia of cancer. In: Murphy MJ, editors. Blood cell cell growth factors: Their present and future use in Hamatology and Oncology. Dayton, Ohio: Alpha Medical press, 1991, p. 121-41.
37. Kaye SB, Lewis CR, Paul J, et al. Randomised study of two doses of cis-platin with cyclophosphamide in epithelial ovarian cancer. Lancet 1992;340:329-33.
38. Oster W, Herrmann F, Cicco A, et al. Erythropoietin prevents chemotherapy-induced anemia: case report. Blut 1990;60:88-92.
39. Schuster SJ, Wilson JH, Erslev AJ, et al. Physiologic regulation and tissue localization of renal erythropoietin messenger RNA. Blood 1987;70:316-8.
40. Ludwig H, Sundal E, Pecherstorfer M, et al. Recombinant human erythropoietin for the correction of cancer associated anemia with and without concomitant cytotoxic chemotherapy. Cancer 1995;76: 2319-29.
41. Goldwasser E, Jacobson LO, Fried W, et al. Studies on erythropoiesis. V. The effect of cobalt on the production of erythropoietin. Blood 1958;13:55.
42. Platanias LC, Miller CB, Mick R, et al. Treatment of chemotherapy-induced anemia with recombinant human erythropoietin in cancer patients. J Clin Oncol 1991;9:2021-6.
43. Spivak JL. Recombinant human erythropoietin and the anemia of cancer. Blood 1994;84:997-1004.
44. Cascinu S, Fedeli A, Del Ferro E, et al. Recombinant human erythropoietin treatment in cis-platin-associated anemia: a randomized, double-blind trial with placebo. J Clin Oncol 1994;12:1058-62.
45. George WJ, Briggs DW, Rodgers GM, et al. Metabolism of erythropoietin. In: Fisher JW, editor. Kidney Hormones, vol. II. New York: Academic press, 1977, p. 73-109.
46. Cascinu S, Fedeli A, Del Ferro E, et al. Recombinant human erythropoietin treatment in cis-platin-associated anemia: a randomized, double-blind trial with placebo. J Clin Oncol 1994;12: 1058-62.
47. Wolff M, Jelkmann W. Effects of chemotherapeutic and immuno-suppressive drugs on the production of erythropoietin in human hepatoma cultures. Ann Hematol 1993;66:27-31.
48. Faquin WC, Schneider TJ, Goldberg MA. Effect of inflammatory cytokines on hypoxia-induced erythropoietin production. Blood 1992;79:1987-94.
49. Means Jr RT, Krantz SB. Inhibition of human erythroid colonyforming units by gamma interferon can be corrected by recombinant human erythropoietin. Blood 1991;78:2564-7.
50. Johnson RA, Waddelow TA, Caro J, et al. Chronic exposure to tumor necrosis factor in vivo preferentially inhibits erythropoiesis in nude mice. Blood 1989;74:130-8.
51. Aoki I, Nishijima K, Homori M, et al. Responsiveness of bone marrow erythroid progenitors (CFU-E and BFU-E) to recombinant human erythropoietin (rh-Ep) in vitro in multiple myeloma. Br J Haematol 1992;81:463-9.
52. Goebel K, von Manteuffel G, Zehner J, et al. Glucocorticoid-induced effect of erythropoietin in haemolytic anaemia with uraemia and red cell enzyme deficiency. Wien Klin Wochenschr 1978;90:690-5.